Deferred Administration of Afobazole Induces Sigma1R-Dependent Restoration of Striatal Dopamine Content in a Mouse Model of Parkinson's Disease

被引:7
|
作者
Kadnikov, Ilya A. [1 ]
Verbovaya, Ekaterina R. [1 ]
Voronkov, Dmitry N. [2 ]
Voronin, Mikhail V. [1 ]
Seredenin, Sergei B. [1 ]
机构
[1] FSBI Zakusov Inst Pharmacol, Dept Pharmacogenet, Baltiyskaya St 8, Moscow 125315, Russia
[2] Res Ctr Neurol, Lab Neuromorphol, Volokolamskoe Highway 80, Moscow 125367, Russia
关键词
chaperone Sigma1R; Parkinson’ s disease; 6-OHDA; dopamine; rotarod; tyrosine hydroxylase; afobazole; PRE-084; BD-1047; SIGMA-1 RECEPTOR CHAPERONE; ENDOPLASMIC-RETICULUM; PROTEASOMAL FUNCTION; BINDING-SITES; ACTIVATION; 6-OHDA; BRAIN; NEURONS; 6-HYDROXYDOPAMINE; NEUROINFLAMMATION;
D O I
10.3390/ijms21207620
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Previously, we demonstrated that the immediate administration of multitarget anxiolytic afobazole slows down the progression of neuronal damage in a 6-hydroxidodamine (6-OHDA) model of Parkinson's disease due to the activation of chaperone Sigma1R. The aim of the present study is to evaluate the therapeutic potential of deferred afobazole administration in this model. Male ICR mice received a unilateral 6-OHDA lesion of the striatum. Fourteen days after the surgery, mice were treated with afobazole, selective Sigma1R agonist PRE-084, selective Sigma1R antagonist BD-1047, and a combination of BD-1047 with afobazole or PRE-084 for another 14 days. The deferred administration of afobazole restored the intrastriatal dopamine content in the 6-OHDA-lesioned striatum and facilitated motor behavior in rotarod tests. The action of afobazole accorded with the effect of Sigma1R selective agonist PRE-084 and was blocked by Sigma1R selective antagonist BD-1047. The present study illustrates the Sigma1R-dependent effects of afobazole in a 6-OHDA model of Parkinson's disease and reveals the therapeutic potential of Sigma1R agonists in treatment of the condition.
引用
收藏
页码:1 / 18
页数:18
相关论文
共 36 条
  • [21] Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA
    Dominguez-Meijide, Antonio
    Villar-Cheda, Begona
    Garrido-Gil, Pablo
    Sierrra-Paredes, German
    Guerra, Maria J.
    Labandeira-Garcia, Jose L.
    NEUROPHARMACOLOGY, 2014, 76 : 156 - 168
  • [22] Treadmill exercise modifies dopamine receptor expression in the prefrontal cortex of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse model of Parkinson's disease
    Kintz, Natalie
    Petzinger, Giselle M.
    Jakowec, Michael W.
    NEUROREPORT, 2017, 28 (15) : 987 - 995
  • [23] Oral Administration of Probiotic Bifidobacterium breve Improves Facilitation of Hippocampal Memory Extinction via Restoration of Aberrant Higher Induction of Neuropsin in an MPTP-Induced Mouse Model of Parkinson's Disease
    Ishii, Toshiaki
    Furuoka, Hidefumi
    Kaya, Motohiro
    Kuhara, Tetsuya
    BIOMEDICINES, 2021, 9 (02) : 1 - 14
  • [24] The effect of striatal pre-enkephalin overexpression in the basal ganglia of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
    Bissonnette, Stephanie
    Muratot, Sophie
    Vernoux, Nathalie
    Bezeau, Francois
    Calon, Frederic
    Hebert, Sebastien S.
    Samadi, Pershia
    EUROPEAN JOURNAL OF NEUROSCIENCE, 2014, 40 (02) : 2406 - 2416
  • [25] EphA1 Activation Induces Neuropathological Changes in a Mouse Model of Parkinson's Disease Through the CXCL12/CXCR4 Signaling Pathway
    Ma, Jianjun
    Wang, Zhidong
    Chen, Siyuan
    Sun, Wenhua
    Gu, Qi
    Li, Dongsheng
    Zheng, Jinhua
    Yang, Hongqi
    Li, Xue
    MOLECULAR NEUROBIOLOGY, 2021, 58 (03) : 913 - 925
  • [26] PROTECTIVE EFFECTS OF VALPROIC ACID ON THE NIGROSTRIATAL DOPAMINE SYSTEM IN A 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE MOUSE MODEL OF PARKINSON'S DISEASE
    Kidd, S. K.
    Schneider, J. S.
    NEUROSCIENCE, 2011, 194 : 189 - 194
  • [27] Striatal dopamine D2, adenosine A2A and cannabinoid CB1 receptors balance as a target against non-cognitive symptoms in a mouse model of Alzheimer's disease
    Gomez-Acero, Laura
    Sanchez-Fernandez, Nuria
    Subirana, Paula
    Ciruela, Francisco
    Aso, Ester
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2025, 249
  • [28] CCL5 promotes LFA-1 expression in Th17 cells and induces LCK and ZAP70 activation in a mouse model of Parkinson's disease
    Zhao, Jingwei
    An, Ke
    Mao, Zhijuan
    Qu, Yi
    Wang, Danlei
    Li, Jiangting
    Min, Zhe
    Xue, Zheng
    FRONTIERS IN AGING NEUROSCIENCE, 2023, 15
  • [29] Prostaglandin E2 EP2 activation reduces memory decline in R6/1 mouse model of Huntington's disease by the induction of BDNF-dependent synaptic plasticity
    Anglada-Huguet, Marta
    Vidal-Sancho, Laura
    Giralt, Albert
    Garcia-Diaz Barriga, Gerardo
    Xifro, Xavier
    Alberch, Jordi
    NEUROBIOLOGY OF DISEASE, 2016, 95 : 22 - 34
  • [30] DJ-1-dependent protective activity of DJ-1-binding compound no. 23 against neuronal cell death in MPTP-treated mouse model of Parkinson's disease
    Takahashi-Niki, Kazuko
    Inafune, Ayako
    Michitani, Naruyuki
    Hatakeyama, Yoshitaka
    Suzuki, Kotaro
    Sasaki, Mai
    Kitamura, Yoshihisa
    Niki, Takeshi
    Iguchi-Ariga, Sanae M. M.
    Ariga, Hiroyoshi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2015, 127 (03) : 305 - 310